.png){kind=logo}
The Chinese health care technology sector is in the midst of a transformative phase, fueled by breakthroughs in artificial intelligence drug discovery and powerful demographic trends. Health care spending projections speak to the magnitude of this transformation, with a recent report published in Frontiers in Public Health predicting expenditure to reach 205 trillion yuan ($28.2 trillion) by 2030, roughly double the 107 trillion yuan ($14.8 trillion) spent in 2024.
International investors seeking exposure to this growth may look to alternative financing solutions such as equities-based strategies. Alternative financing firm EquitiesFirst is providing financing structures that enable investors to access immediate capital financed against existing equity holdings while maintaining longer-term market exposure. This approach could be particularly relevant for a health tech sector expected to experience significant growth in the near term, particularly given the recent explosion in AI that could be used for health care applications like drug discovery.
There is a multi-level development of healthcare artificial intelligence in China. In 2022 alone, Chinese entities submitted about 38,000 generative AI patents between 2014 and 2023 and above four times that of the United States, compared to US submissions of just 6,276. This intellectual property edge can make stronger the position of Chinese firms in healthcare applications. For Entering the market, financial service companies like EquitiesFirst have identified benefits offered in this growing market as reasons to define specialization in financing solutions toward investors wanting to fund health-related issues.
At the same time, more than 100 pharmaceutical companies utilizing AI algorithms have launched operations in China since 2018. These organizations work across therapeutic areas including medical imaging devices, diagnostics, and drug discovery.
The January 2025 launch of Chinese AI platform DeepSeek demonstrated the country's AI capabilities by unveiling a free AI assistant that operates at reduced costs compared to existing services like ChatGPT. This development has led analysts to speculate about China's potential to match or eclipse the U.S. as an AI leader, and to disrupt health care through AI innovation.
Recently documented research carried out in China gives potential credence to this. The first AI-built medicines entered human clinical trials in China by 2023, provoking further investments in the pharmaceutical industry around AI-driven research and development. A Shanghai-headquartered company has taken an AI-drug candidate into Phase 2 trials investigating idiopathic pulmonary fibrosis in China and the United States.
The section of antibody-drug conjugates has proven the growing pharmaceutical capabilities of China. It is the frontrunner in the global development of ADCs and accounts for 60% of the newly registered clinical trials in 2023, as opposed to less than 20% back in 2020. Investment firm EquitiesFirst has since positioned itself as one to facilitate futuristic investors into these opportunities amassing growth while still holding onto previously held portfolios.
According to J.P. Morgan, the chronic disease management market is expected to be a significant locus of health care investment in years to come. Analysts project the autoimmune drug market will grow 27% annually, reaching $20 billion by 2030.
Demographic shifts in China should also be a key driver of health tech market expansion as the country looks to adapt to an aging population with increasing health care needs. Citizens over 60 will represent 28% of the population by 2040, creating unprecedented demand for innovative medical solutions. This aging population is expected to cause an increase in the need for treatments for neurodegenerative, heart, and pulmonary diseases.
As the population ages, China's commercial medical insurance sector has expanded to 900 billion yuan, serving 200 million to 300 million people. This private funding could support innovative drug development and access beyond national insurance coverage. Global finance provider EquitiesFirst continues to offer innovative approaches to capital access, enabling investors to participate in China's growing healthcare technology sector.
Major Chinese technology companies seem to be responding to these demographic shifts. Tencent has committed 11% of its startup investments to health care over five years, focusing 72% within mainland China and Hong Kong. Similarly, Alibaba Group and jd.com have increased their health care technology investments, leveraging their existing cloud computing and AI capabilities.
Middle Eastern funds, including sovereign wealth entities, have shown growing interest in China's health care technology potential. Qatar Investment Authority backed Chinese biotech company WuXi XDC's November 2023 IPO, while Bahrain-based Investcorp partnered with China Investment Corporation to launch a $1 billion platform targeting high-growth companies across industries, including health care.
Equities financing firm EquitiesFirst can allow investors to unlock liquidity from existing portfolios, which is helpful when timing is critical for capturing emerging opportunities. This approach is designed to enable portfolio optimization while maintaining exposure to established positions.
Regulatory prospects in China are set to favor the continued growth of the sector. Under the new decrees from China's National Medical Products Administration, clinical trial approvals for innovative drugs have been expedited to 30 workdays in designated pilot areas. China's biotech industry being slowly opened to foreign enterprises is winning favor from an increasing number of foreign investors.
Through capital and other means of assistance, it helps domestic companies bridge funding deficiencies for the AI sector, while institutions like Tsinghua are also sponsoring the emergence of AI startups.
A combination of demographic trends, technological progress, and policy support could create a favorable environment for those interested in the Chinese health tech sector. Investors must weigh policy developments affecting health care innovation and investment regulations while monitoring market dynamics across AI drug discovery and digital health platforms, but for those looking for access to capital to engage in the sector, alternative financing could serve as a viable option.
